Search academic texts

Information × Registration Number 0221U106404, 0118U003731 , R & D reports Title Improve the treatment of primary lymphoma patients with B cellular origin popup.stage_title Head Kriachok Iryna A., Registration Date 06-12-2021 Organization National Cancer Institute popup.description2 The object of study - non-Hodgkin's lymphoma, immunohistochemical and molecular genetic factors of the disease. The aim of the work is to determine the role of immunohistochemical and molecular genetic markers in the prognosis of non-Hodgkin's diffuse B-cell lymphomas, to optimize the treatment of patients with non-Hodgkin's diffuse B-cell lymphomas using the latest chemotherapy regimens. The study and analysis of the immunohistochemical profile of tumor tissue in lymphomas of B-cell origin and molecular genetic features of the tumor, using the method of flow cytometry. It was determined that among the biological factors, the expression of bcl2 protein has a negative prognostic value for the course of diffuse B-cell lymphoma, regardless of the type of therapy received by the patient. Thus, the rate of 2-year event-free survival in the presence of bcl2 protein expression was (52.6 ± 6.3)% versus (83.9 ± 10.5)% in the absence of its expression (p = 0.02), and the rate of 2 -annual overall survival - 63.4 versus 92.3%, respectively (p = 0.03). The prognostic value of positron emission tomography in primary patients with Hodgkin's lymphoma was determined. A statistically significant difference in the level of BRV in patients with LH with different indicators of Deauville 5-PS in the assessment of PET-2. Three-year BRV in patients with PET-2 according to the Deauville scale 1-2 compared to Deauville4-5 points was 90.7% versus 46.3%, respectively (P <0.004). The level of 3-year BRV in patients with PET-2 Deauville 3 vs. Deauville 4–5 was 85.7% vs. 46.3%, respectively (P <0.05). Multivariate analysis did not show a statistically significant correlation between PET-2 + and extranodal lesions or large tumor mass. 88.8% (79/89) and 11.2% (10/89) of patients in the study group had the status of PET-3-negative (PET-3-) and positive (PET-3 +), respectively (p <0 , 05). The majority of patients with early and late stages of the disease achieved complete remission. Product Description popup.authors Aleksyk Olena M Martynchyk Arina V Titorenko Iryna B popup.nrat_date 2021-12-06 Close